SCHEMBL7756995

SCHEMBL7756995

Nc1nc(Nc2ccccc2)sc1C=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.68
MEN1 O00255 6/20 0.68
KMT2A Q03164 6/20 0.68
LMNA P02545 4/20 0.68
PSMD14 O00487 1/20 0.68
CCNA2 P20248 8/20 0.55
CDK2 P24941 8/20 0.55
CDK5 Q00535 4/20 0.55
CDK5R1 Q15078 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
GSK3B P49841 2/20 0.55
GSK3A P49840 1/20 0.55
MAPK14 Q16539 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
CSNK2A1 P68400 1/20 0.46
PLK3 Q9H4B4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1248205 0.84 CDK5 (0.58) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL13675041 0.81 GSK3A (0.54) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL7756093 0.81 MAPT (1.00) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1250757 0.81 MAPT (0.52) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1248421 0.78 CCNA2 (0.49) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL5553339 0.77 MAPT (0.51) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1247904 0.77 GSK3B (0.48) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1249747 0.75 MAPT (0.46) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL7757552 0.74 CCNA2 (0.76) MAPTMEN1KMT2ALMNACCNA2
SCHEMBL7753436 0.74 CCNA2 (0.76) MAPTMEN1KMT2ALMNACCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives NOVO NORDISK A/S (DK) 2001-11-08 US disclosed
WO-2001056567-A1 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS NOVO NORDISK A/S (DK) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives GSK3A, GSK3B, GSKIP MAPT 13/4885MEN1 3396/4885KMT2A 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.